List view / Grid view
Prof. Klaus Dugi serves as Corporate Senior Vice President of Medicine and Chief Medical Officer at Boehringer Ingelheim GmbH.
Boehringer Ingelheim announced the upcoming presentation of new data on…
26 August 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013...
Data published in The Lancet showed that elderly people with…
15 August 2013 | By OgilvyHealthPR London
Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo. In addition, the…
Boehringer Ingelheim announced that enrolment of over 950 treatment naïve…
15 August 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced that enrolment of over 950 treatment naïve genotype-1b patients in the pivotal Phase III interferon-free HCVerso™ 1 and 2 trials is complete...
Data from the LUX-Lung clinical trial programme...
1 August 2013 | By Boehringer Ingelheim
Data from the LUX-Lung clinical trial programme...
Boehringer Ingelheim (BI) and Eli Lilly and Company today announced…
31 July 2013 | By Boehringer Ingelheim
Boehringer Ingelheim (BI) and Eli Lilly and Company today announced enrollment of the first patient into a cardiovascular and renal outcomes trial for linagliptin (Trajenta®). The CARMELINA1 (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with Type 2 Diabetes mellitus at high vascular risk) trial will investigate the…
"Boehringer Ingelheim welcomes the decision by the CHMP..."
26 July 2013 | By Boehringer Ingelheim
"Boehringer Ingelheim welcomes the decision by the CHMP..."
BI and EFSD commit €2.5 million to help accelerate European…
17 July 2013 | By Boehringer Ingelheim
BI and EFSD commit €2.5 million to help accelerate European initiatives...
Boehringer Ingelheim announced the submission of an application to the…
24 June 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the submission of an application to the EMA...
New long-term data from the RELY-ABLE® study...
17 June 2013 | By Boehringer Ingelheim
New long-term data from the RELY-ABLE® study...
Data from interferon-free SOUND-C3 study...
13 June 2013 | By Boehringer Ingelheim
Data from interferon-free SOUND-C3 study...
New findings presented...
8 June 2013 | By Boehringer Ingelheim
New findings presented...
LUME-Lung 1 results represent the first advance in almost a…
3 June 2013 | By Boehringer Ingelheim
LUME-Lung 1 results represent the first advance in almost a decade...
Data from Boehringer Ingelheim’s LUX-Lung 6 trial...
1 June 2013 | By Boehringer Ingelheim
Data from Boehringer Ingelheim’s LUX-Lung 6 trial...
Results from the pivotal Phase III STARTVerso™1 trial...
23 April 2013 | By Boehringer Ingelheim
Results from the pivotal Phase III STARTVerso™1 trial...
“We are pleased with the promising results..."
26 March 2013 | By Ogilvy HealthPR London
“We are pleased with the promising results..."
